SGLT 2 inhibitors: Antidiabetic agents with promising effects beyond glucose control by Canan Ersoy

Subjects: “…sglt2 inhibitor…”
Get full text

Multicenter, open label, randomized controlled superiority trial for availability to reduce nocturnal urination frequency: The TOP‐STAR study by Hanako Nakajima, Hiroshi Okada, Akinori Kogure, Takafumi Osaka, Takeshi Tsutsumi, Masayoshi Onishi, Kazuteru Mitsuhashi, Noriyuki Kitagawa, Shinichi Mogami, Akane Kitamura, Michiyo Ishii, Naoto Nakamura, Akio Kishi, Sato Eiko, Masahide Hamaguchi, Michiaki Fukui

Subjects: Get full text

Blood Pressure Reduction and Changes in Antihypertensive Medication Use Among Patients With Hypertension Who Initiated Sodium‐Glucose Cotransporter‐2 Inhibitors by Jaejin An, John J. Sim, Matt M. Zhou, Hui Zhou, Soon Kyu Choi, Jeffrey W. Brettler, Angeline L. Ong‐Su, Kristi Reynolds

Subjects: Get full text

Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage and Dietary Administration by... by Kawarasaki S, Sawazaki H, Iijima H, Ng SP, Kwon J, Mohri S, Iwase M, Jheng HF, Takahashi H, Nomura W, Inoue K, Kawada T, Goto T

Subjects: “…sglt2 inhibitor…”
Get full text

Linezolid-Induced Pancytopenia in Patients Using Dapagliflozin: A Case Series by Li MM, Shen WC, Li YJ, Teng J

Subjects: Get full text

Sodium–glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusions by D'Elia JA, Segal AR, Bayliss GP, Weinrauch LA

Subjects: “…SGLT2 inhibitor…”
Get full text

Case Report: High-Calorie Glucose Infusion and Tight Glycemic Control in Ameliorating Refractory Acidosis of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis by Siti Sanaa Wan Azman, Norlela Sukor, Muhammad Yusuf Abu Shamsi, Ilham Ismail, Nor Azmi Kamaruddin

Subjects: Get full text

High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination by Marvin Wei Jie Chua

Subjects: “…SGLT2 inhibitor…”
Get full text

SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans by Heeyoung Chae, Robert Augustin, Eva Gatineau, Eric Mayoux, Mohammed Bensellam, Nancy Antoine, Firas Khattab, Bao-Khanh Lai, Davide Brusa, Birgit Stierstorfer, Holger Klein, Bilal Singh, Lucie Ruiz, Michael Pieper, Michael Mark, Pedro L. Herrera, Fiona M. Gribble, Frank Reimann, Anne Wojtusciszyn, Christophe Broca, Nano Rita, Lorenzo Piemonti, Patrick Gilon

Subjects: Get full text

Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS‐MI): rationale and design by Jaclyn Carberry, Mark C. Petrie, Matthew M.Y. Lee, Katriona Brooksbank, Ross T. Campbell, Richard Good, Pardeep S. Jhund, Peter Kellman, Ninian N. Lang, Kenneth Mangion, Patrick B. Mark, Alex McConnachie, John J.V. McMurray, Barbara Meyer, Vanessa Orchard, Aadil Shaukat, Stuart Watkins, Paul Welsh, Naveed Sattar, Colin Berry, Kieran F. Docherty

Subjects: Get full text

SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM by Birdie Huang, Chieh-Li Yen, Chao-Yi Wu, Chung-Ying Tsai, Jia-Jin Chen, Ching-Chung Hsiao, Yung-Chang Chen, I.-chiang Hsieh, Huang-Yu Yang

Subjects: Get full text

Evaluation of safety and anti-obesity effects of DWP16001 in naturally obese dogs by Beomseok Rhee, Rahman Md Mahbubur, Changfan Jin, Ji-Soo Choi, Hyun-Woo Lim, Wan Huh, Joon Seok Park, Jumi Han, Sokho Kim, Youngwon Lee, Jinho Park

Subjects: Get full text

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin by Julio Rosenstock, Chantal Mathieu, Hungta Chen, Ricardo Garcia-Sanchez, Gabriela Luporini Saraiva

Subjects: Get full text

Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review by Koichiro Matsumura, Tetsuro Sugiura

Subjects: Get full text

Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review by Makoto Fujiwara, Makoto Fujiwara, Masaru Shimizu, Masaru Shimizu, Tatsuya Okano, Yuko Maejima, Kenju Shimomura

Subjects: Get full text

Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study by Johan Mårtensson, Salvatore Lucio Cutuli, Eduardo A. Osawa, Fumitaka Yanase, Lisa Toh, Luca Cioccari, Nora Luethi, Akinori Maeda, Rinaldo Bellomo

Subjects: “…SGLT2 inhibitor…”
Get full text

Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus by Hyun A Cho, Young Lee Jung, Yong Hoon Lee, Yu Chang Lee, Jung Eun Lee, Sol Jae Lee, Su Jin Jeong, Chong Hwa Kim

Subjects: “…SGLT2 inhibitor…”
Get full text

Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus by Yuta Suzuki, Hidehiro Kaneko, Akira Okada, Hidetaka Itoh, Satoshi Matsuoka, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Kentaro Kamiya, Atsuhiko Matsunaga, Junya Ako, Koichi Node, Hideo Yasunaga, Issei Komuro

Subjects: “…SGLT2 inhibitor…”
Get full text

Interaction Between Non-Insulin Glucose-Lowering Medication and Exercise in Type 2 Diabetes Mellitus – New Findings on SGLT2 Inhibitors by Christian Brinkmann, Christian Brinkmann

Subjects: Get full text

Empagliflozin: a potential anticancer drug by Wenwen Wu, Yanyan Wang, Jun Xie, Shaohua Fan

Subjects: Get full text